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Expression of the hepatitis B virus S protein
results in the formation of a lipoprotein particle,
the hepatitis B surface antigen (HBsAg). Such
particles, produced inSaccharomyces cerevisiae,
bind to the cell surface of monocytes through
interaction with the lipopolysaccharide binding
protein and the lipopolysaccharide receptor,
CD14. This attachment is suggested to depend
on the presence of charged phospholipids in
the particles. In addition, such particles interfere
with the lipopolysaccharide and interleukin-2-
induced activation of monocytes. In the present
study, it is reported that of three Saccharomyces
cerevisiae-derivedHBsAgpreparations, twohave
a reduced capacity to bind to monocytes. A cor-
relation with a reduced potential to inhibit the
lipopolysaccharide-induced activation of mono-
cytes and an increased potential to stimulate
HBsAg-specific T-cell proliferation is observed.
Surprisingly, differences in phospholipid content
that might explain these observations, were not
detected. J. Med. Virol. 70:513–519, 2003.
 2003 Wiley-Liss, Inc.
KEY WORDS: rHBsAg; CD14; lipopolysacchar-
ide binding protein; phospholi-
pid; lipopolysaccharide
INTRODUCTION
HepatitisB virus (HBV)-infectedhepatocytes produce
and secrete noninfectious particles, hepatitis B surface
antigen (HBsAg). HBsAg consists mainly of spherical
particles of 22-nm diameter and a small number of
filamentous particles. These particles canaccumulate to
several 100 mg/ml in the circulation. The spherical
particles contain viral-encoded membrane proteins and
approximately 30% (by weight) of host cell-derived
lipids. The S protein accounts for more than 90% of the
protein contained in HBsAg. The L andM proteins form
the remainder. These three proteins share 226 C-
terminal amino acids. Both glycosylated and nonglyco-
sylated forms of these viral membrane proteins are
present in the particles [Seeger and Mason, 2000]. In
1981, a plasma-derived HBsAg vaccine was licensed in
theUnitedStates.Plasma-derivedHBsAg in thevaccine
was soon replaced by recombinant HBsAg, produced in
Saccharomyces cerevisiae. More recently, HBsAg pro-
duced in other yeasts (Hansenula polymorpha and
Pichia pastoris) and mammalian cells is also being
used. In contrast to the plasma and mammalian cell-
derived HBsAg, the different yeast-derived HBsAg
particles contain only the nonglycosylated S-protein.
Despite these differences in protein content and protein
modifications, it is generally accepted that, both struc-
turally and antigenically, the yeast-derived HBsAg
closely resembles the natural and mammalian cell-
derived HBsAg.
Recently, it was shown that S. cerevisiae-expressed
HBsAg (rHBsAg) suppressed the lipopolysaccharide
(LPS) and interleukin-2 (IL-2)-induced production of
proinflammatory cytokines, while upregulating the
LPS-induced expression of the anti–inflammatory IL-
10 by humanmonocytes [Vanlandschoot et al., 2002a,c].
Moreover, the preferential binding of rHBsAg to the
monocytes of peripheral blood mononuclear cells
(PBMCs) was observed [Vanlandschoot et al., 2002a].
The LPS receptor (CD14) was shown to be necessary for
theattachment of rHBsAg to occur.A serumprotein that
enhanced the binding of rHBsAg to monocytes was
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identified as the lipopolysaccharide binding protein
(LBP) [Vanlandschoot et al., 2002b]. Surprisingly, it
was found that HBsAg, purified from plasma (pHBsAg),
was not endowedwith this property of binding in a LBP-
dependent manner to the surface of CD14-expressing
cells. Experimental evidence was presented that
charged phospholipids, not or no longer present in
pHBsAg, were responsible for the interaction of rHBsAg
with the (cellular) receptors [Vanlandschoot et al.,
2002b]. Because of this difference between pHBsAg
and rHBsAg, it was considered important to investigate
whether HBsAg expressed in other yeasts or mammal-
ian cells, might show differences in attachment to
monocytes, and their capacity to interfere with the
LPS-induced activation of monocytes. Several vaccine
producers of HBsAg were contacted, but none was
willing to supply HBsAg. The study was therefore
limited to the use of three different lots of S. cerevisiae-
expressed rHBsAg, obtained form GlaxoSmithKline.
Nevertheless, clear differences in binding, immune
suppression, and T-cell immunogenicity were observed
among these preparations.
MATERIALS AND METHODS
rHBsAg
Three rHBsAg (subtype adw2) preparations produced
in S. cerevisiae were kindly provided by GlaxoSmithK-
lineBiologicals (Rixensart, Belgium).DVP93/1 (1,000 mg/
ml) were produced and purified in 1993, and HEF002
(1,096 mg/ml) and HEP715 (1562 mg/ml) in 2000. These
rHBsAg particles were dissolved in phosphate-buffered
saline (PBS); no adjuvant or preservatives were added.
The purity of the rHBsAg preparations was judged by
high-performance liquid chromatography (HPLC)
analysis, as well as by sodium dodecyl sulfate-polyacryl-
amide gel electrophoresis (SDS-PAGE) with Coomassie
staining and is >98%. rHBsAg is composed of well-
defined subviral particles, which contain only the non-
glycosylated S protein. Similar preparations are used
worldwide as human HBV vaccines after adsorption on
to aluminum hydroxide.
rHBsAg (DVP93/1) was biotinylated using an
enhanced chemiluminescence system (ECL) protein
biotinylationmodule (RPN2202, AmershamPharmacia
Biotech) as described by Vanlandschoot et al. [2002a].
Biotinylated rHBsAg (b-rHBsAg) was purified by gel
filtration on a Sephadex G25 column using PBS; 1-ml
fractions were collected, and the two b-rHBsAg peak
fractions were pooled.
Enzyme-Linked Immunosorbent Assay
Maxisorb 96-well plates (Nunc, Roskilde, Denmark)
were coatedwith rHBsAgorb-rHBsAg inPBS.Thewells
were blocked with 0.1% bovine serum albumin (BSA) in
PBS, followed by three washings (PBS, 0.1% Triton
X-100). HBsAg-specific monoclonal antibodies (MAb;
1 mg/ml) or horseradish peroxidase (HPO)-labeled strep-
tavidin (SAPE) were added, and the plates were
incubated for 1 hr at room temperature. Antibodies
were detectedwith peroxidase-labeled goat-anti-human
antibodies (Sigma). After three washings, 3.30,5,50-
tetramethylbenzidine (Sigma) was added. After 30 min,
the reaction was stopped with 1 N H2SO4.
Antibodies
Human anti-HBsAg MAb F47B was a kind gift from
Lia Sillekens (Centraal Laboratorium van de Bloed-
bank, Amsterdam). The human anti-a MAb, which
recognizes the ‘‘a’’ determinant ofHBsAg,wasdeveloped
in the laboratory and biotinylated as described above for
rHBsAg. For fluorescence-activated cell sorting (FACS)
analysis, human antibodies were detected with rabbit
anti-humanF(ab0)2-FITC. Phycoerythrin-labeled strep-
tavidin (Strep-PE)was obtained fromBectonDickinson.
LPS Binding Protein
LBP was expressed in Chinese hamster ovary (CHO)
cells and was purified as described [Stelter et al., 1999].
Cells
Human peripheral blood mononuclear cells (PBMCs)
were isolated from buffy coats, using Ficoll-Hypaque
centrifugation (density¼ 1.077 g/ml; Nycomed Pharma,
Oslo, Norway). Cells were stored in liquid nitrogen.
THP-1 cells were grown in cRPMI (RPMI 1640–10%
fetal cell serum [FCS], 2 mM L-glutamine, 1 mM Na-
pyruvate, 50 U/ml penicillin, 50 mg/ml streptomycin,
20 mM b-mercaptoethanol). To induce differentiation,
100 nM 1,25-dihydroxy vitamin D3 (Calbiochem) was
added for 24 hr. CHO cells that express human CD14
and CHO cells transfected with the empty vector only
[Jack et al., 1995; Stelter et al., 1997] were grown
in MEM-a without nucleosides and ribonucleosides
(Gibco-BRL) supplemented with 10% FCS, 2 mM L-
glutamine, 50 U/ml penicillin, 50 mg/ml streptomycin,
100 nM (plasmid-transfected CHO cells), or 500 nM
methotrexate (CHO cells that express CD14). Cultured
cells were detached mechanically or with nonenzymatic
cell dissociation buffer (Sigma), washed twice with 2%
human AB serum (Bio-Whitaker) in Hank’s balanced
salt solution (HBSS; Gibco-BRL) (2% HS-HBSS), and
stained as described below.
Staining of Cells
PBMCs were thawed and washed twice with 2% HS-
HBSS; 106 cells were incubated with b-rHBsAg or
rHBsAg in 200 ml HBSS for 90 min on ice. During this
incubation, 2% HS or 0.5 mg/ml LBP was added as in-
dicated.Human serumused in these binding assayswas
not heat-inactivated. After two washings with the same
solution, cells were incubated with Strep-PE or HBsAg-
specific antibodies, followed by FITC-labeled antibodies
in 2%HS-HBSS for 1 hr on ice. After twowashings, cells
were resuspended in 1 ml 2% HS-HBSS or PBS, con-
taining propidium iodide (PI). Cells were analyzed on a
FACScanflowcytometer (BectonDickinson).Dead cells,
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which incorporated PI, were gated out of analysis. At
least 5,000cellswere countedper analysis.Fluorescence
(530 nm for FITC and 580 nm for PE) was measured.
Median fluorescence was determined in each case. The
signals were acquired in a logarithmic mode for FL1
(FITC) and FL2 (PE). Threshold levels were set accord-
ing to negative (Strep-PE only) and isotypic controls.
LPS Treatment of THP-1
In this study, 3.105 THP-1 cells were treated for
24 hr with 100 nM 1,25-dihydroxy vitamin D3. After
washing, the cells were incubated in cRPMI with or
without 10 ng/ml LPS (Escherichia coli 0111:B4, Sigma);
0, 1, 10, 25, or 50 mg/ml rHBsAg was added. Cell
supernatants were collected after 4 hr and were tested
for the presence of tumor necrosis factor-a (TNF-a).
Cytokine Determinations
The concentration of TNF-a in cell supernatant was
determined using commercially available kits (Bio-
source) according to the manufacturer’s instructions.
Lymphoproliferation Assay
Unfractionated PBMCs were suspended in RPMI
1640 medium supplemented with 25 mM Hepes, 50 U/
ml penicillin, 50 mg/ml streptomycin, 2 mM L-glutamin,
5105 M b-mercaptoethanol, and 10% heat-inacti-
vated human AB serum. PBMCs (2105/well) from
vaccinated or HBV-infected subjects were cultured for
6 days (378C in 5% CO2) in 96-well round-bottomed
microtiter plates containing rHBsAg particles at the
concentrations indicated. All assays were carried out in
triplicate, and 3H-TdR (0.5 mCi/well, Amersham Inter-
national, UK) was added 18 hr before termination.
Cultures were harvested using an automated harvest-
ing device and were assayed for 3H-TdR incorporation
by liquid scintillation counting in an LKB-Wallac 8100
Counter.
Phospholipid Extraction, Determination,
and Quantification
Phospholipids were extracted according to a modified
Bligh and Dyer method [Bligh and Dyer, 1959;
Weerheim et al., 2002]. Phospholipids were determined
and quantified by high-performance thin-layer chroma-
tography (HPTLC) as described [Weerheim et al., 2002].
RESULTS
Reduced Attachment of HEF002
and HEP715 to CD14þ Cells
Two different methods were used to compare the
binding capacities of the three rHBsAg preparations.
The first assay was based on the antibody-mediated
detection of rHBsAg bound to the surface of CHO cells
that express CD14. However, this method requires that
the different particles show a similar reactivity toward
the antibody used. Using two different human MAbs
(anti-a and F47B) the antigenic quality of the three
preparations was shown to be similar (Fig. 1). More
importantly, the results demonstrated that antibody
F47B could be used to compare the binding of these
rHBsAg preparations to the cell surface. The second
assay was based on the capacity of nonbiotinylated
rHBsAg to compete with the binding of biotinylated
rHBsAg, derived from DVP93/1, to monocytes of
PBMCs.
Fig. 1. Antigenic structure of DVP93/1, HEF002, and HEP715 is very similar. Enzyme-linked
immunosorbent assay (ELISA) plates were coated with DVP93/1 (black circles), HEF002 (gray circles),
and HEP715 (white circles). After blocking with bovine serum albumin (BSA), human monoclonal
antibodies (MAbs) F47B (left) and anti-a (right) were allowed to bind to the particles. MAbs were detected
with goat-anti human peroxidase-labeled antibodies.
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CHO cells that expressed CD14 were incubated on ice
with2mg/ml rHBsAgand0.5mg/mlLBP inHBSS.Bound
rHBsAg was detected using antibody F47B and rabbit
anti-humanF(ab0)2-FITC. As shown inFigure 2, attach-
ment of HEF002 en HEP715 to the cell surface was five
to six times lower as compared with the attachment of
DVP93/1.
As shown in Figure 3, the use of 5 mg/ml of non-
biotinylated DVP93/1 led to a reduction in binding of
biotinylated DVP93/1 by more then 50%. A similar
reduction required the use of 50 mg/ml HEF002 and
HEP715. Taken together, these results demonstrated
clearly the reduced capacity of these two rHBsAg pre-
parations to bind to the cell surface of CD14-expressing
cells.
HEF002 and HEP715 have a Reduced
Capacity to Inhibit LPS-Induced
Activation of THP-1 Cells
Previously, it was demonstrated that the coadminis-
tration of LPS and rHBsAg to monocytes or THP-1 cells
led to a substantial inhibition in LPS-induced TNF-a
secretion [Vanlandschoot et al., 2002a,c]. To determine
whether the reduced binding of HEF002 andHEP715 to
CD14þ cells, correlated with a reduced inhibition of
LPS-induced activation of monocytes, the THP-1 assay
was used. Because THP-1 cells do not express CD14,
cells were first treated with 100 nM 1,25-dihydroxy
vitamin D3. Differentiated THP-1 cells were incubated
with LPS in the presence of different concentrations of
rHBsAg. Culture supernatant was collected after 4 hr of
stimulation and tested for the presence of TNF-a. At this
4-hr time point, secretion has reached its maximum
[Vanlandschoot et al., 2002c]. As shown in Figure 4, a
dose-dependent reduction of TNF-a secretion was
observed when cells were stimulated with LPS in the
presence of rHBsAg. However, using 50 mg/ml of
rHBsAg, this reduction was twofold only for HEF002
and HEP715, while a 20-fold reduction was obtained
using DVP93/1.
Enhanced Immune Recognition of HEP715
by PBMCs from High-Responder
Hepatitis B Vaccinees
The observation of differences in binding among
rHBsAg preparations, despite the fact that all were
derived from the same yeast species, was rather
unexpected. The observation that reduced binding could
be correlated with reduced inhibition of LPS-induced
activation of monocytes raised the idea that the
immune-suppressive attachment to monocytes might
influence the HBsAg-specific T-cell proliferation. If this
assumption was correct, an enhanced proliferation
was predicted when using the low binding rHBsAg
preparations.
The proliferative response of HBsAg-specific T cells
toward the three rHBsAg preparations was investi-
Fig. 2. Reduced attachment of HEF002 and HEP715 to Chinese
hamster ovary (CHO)-CD14. CHO-CD14 cells were incubated for
90 min on ice with 2 mg/ml of the different preparations together with
0.5 mg/ml lipopolysaccharide binding protein (LBP) in Hank’s balanced
salt solution (HBSS). Particles were detected using monoclonal anti-
body (MAb) F47B. Median fluorescence was determined. The data
represent the mean of three separate experiments. Error bars
represent SD.
Fig. 3. Reduced inhibition of biotinylated S. cerevisiae-expressed
hepatitis B surface antigen (b-rHBsAg) binding to monocytes by
nonbiotinylated HEF002 and HEP715. Peripheral blood mononuclear
cells (PBMCs) were incubated with different amounts of DVP93/1
(black bars),HEF002 (gray bars), andHEP715 (white bars) in 200 ml 1%
HS-Hank’s balanced salt solution (HBSS). After 90min, b-rHBsAgwas
added and the cells were incubated for another hour. After twowashes,
cells were stained with Strep-PE. Median fluorescence was deter-
mined. The data represent the mean of three separate experiments.
Error bars represent SD. The bar on the left represents binding of
b-rHBsAg.
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gated, using unfractionated PBMCs from rHBsAg vac-
cinees (two high and two nonresponders) and two
chronically infected patients. Increasing doses of
rHBsAg were added to 2105 PBMCs. rHBsAg-specific
proliferation was not observed for PBMCs derived from
nonresponders vaccinees and chronically infected
patients (Fig. 5). PBMCs fromall donors, except patient,
proliferated when challenged with tetanus toxoid. This
demonstrates that the lack of a response is specific for
rHBsAg. HEP715 caused a significant higher prolifera-
tion (two- to fourfold) with PBMCs derived from the two
different high responders, compared with the prolifera-
tion observed with DVP93/1.
DVP93/1, HEF002, and HEP715 Contain Similar
Amounts of Phosphatidylinositol
Previously, it was reported that charged phospholi-
pids determine whether binding of HBsAg to monocytes
occur [Vanlandschoot et al., 2002b]. Because of the
differences in attachment observed among DVP93/1,
HEF002, and HEP715, it was expected to find differ-
ences in phospholipid content. However, as shown in
Table I, the phospholipid content of DVP93/1, HEF002,
and HEP715 was almost completely identical.
DISCUSSION
Since 1986, millions of doses of vaccines containing
the S. cerevisiae-derived HBsAg have been adminis-
tered. These vaccines are safe and immunogenic and
have reduced the occurrence of hepatitis B infections in
the targeted populations [Leroux-Roels et al., 2001].
HBsAg, purified from plasma, contains the three viral
membrane proteins, which are partially glycosylated.
Compared with the natural HBsAg, this yeast-derived
HBsAg only contains the S protein, which is nonglyco-
sylated. Another known difference, which attracted
little attention, is the presence of phosphatidylinositol
in the yeast-expressed HBsAg. This phospholipid is
absent in the natural HBsAg particles. The phospholi-
pids of S. cerevisiae-derived HBsAg have also been
shown to contain much more smaller (C16/C18¼ 1.759)
fatty acids compared with the natural HBsAg (C16/
C18¼0.484). In addition, S. cerevisiae-derived HBsAg
contains more unsaturated fatty acids. As a result, the
fluidity of S. cerevisiae-derived HBsAg lipid content is
higher [Gavilanes et al., 1982; Van der Meeren et al.,
1994]. The possible consequences of these differences in
the lipid content and lipid structure have hardly been
studied. Recent observations nevertheless demonstrate
that such differences have unexpected consequences:
S. cerevisiae-derived HBsAg, and not plasma-derived
HBsAg, was shown to bind to monocytes through
interaction with the LPS binding protein and CD14.
Upon detergent removal of the lipids and reconstitution
of the proteins with charged phospholipids like phos-
phatidylserine and phosphatidylglycerol, binding of
natural HBsAg was observed [Vanlandschoot et al.,
2002b]. Because phosphatidylinositol is the only charg-
ed phospholipid found in Saccharomyces-expressed
HBsAg [VanderMeeren et al., 1994; also data presented
above], it was proposed that this lipid determines the
interaction of rHBsAg with monocytes.
Initially, the purpose of the present study was to
compare binding of HBsAg expressed in different yeast
species (S. cerevisiae and H. polymorpha) and mamma-
lian cells with monocytes and to investigate their
immune-suppressive potential. The lipid content of
HBsAg expressed in these hosts is indeed variable
[Van der Meeren et al., 1994; Diminsky et al., 1997].
However, obtaining vaccine HBsAg for this research
purpose was difficult. The study was therefore limit-
ed to the use of three different lots of S. cerevisiae-
expressed rHBsAg, obtained from GlaxoSmithKline.
Surprisingly, the results of two different binding assays
Fig. 4. Reduced inhibition of lipopolysaccharide (LPS)-induced secretion of tumor necrosis factor-a
(TNF-a) by HEF002 and HEP715; 3 105 1,25-dihydroxy vitamin D3 differentiated THP-1 cells were
incubated with 10 ng/ml LPS and different concentrations of DVP93/1 (left), HEF002 (middle), and
HEP715 (right). Cell supernatant was collected after 4 hr and cytokine concentrations determined. The
data represent the mean of three separate experiments. Error bars represent SD.
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Fig. 5. IncreasedT-cell recognition ofHEP715byhepatitisBhigh-respondervaccinees. Increasingdoses
of DVP93/1 (black bars), HEF002 (gray bars) and HEP715 (white bars) were added to 2105
unfractionated PBMCs of 2 Hepatitis B high-responder vaccinees (upper panels), 2 non-responder
vaccinees (middle panels) and 2 chronically infected patients (lower panels). Lymphoproliferation was
measured after 6 days of culture. Data show the mean of three wells. Error bars represent SD.
TABLE I. Phospholipid Content of DVP93/1, HEF002, and HEP715
DVP93/1 HEF002 HEP715
ng ng/mg % ng ng/mg % ng ng/mg %
Lyso PC 24 4.8 1.4 16 2.9 0.9 35 4.5 1.4
PC 1,038 207.6 60.8 1,005 183.4 57.7 1,377 176.3 54.6
PI 543 108.6 31.8 589 107.5 33.8 889 113.8 35.2
PE 101 20.2 5.9 132 24.1 7.6 222 28.4 8.8
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demonstrated clearly the reduced capacity of two
rHBsAg preparations to bind to the cell surface of
CD14-expressing cells. This reduced binding correlat-
ed with a 10-fold lower inhibition of LPS-induced
secretion of TNF-a by THP-1 cells. When the T-cell
immunogenicity was examined, a two- to fourfold
higher proliferation was obtained, only with HEP715.
This enhanced T-cell recognition was observed with
PBMCs from high-responder vaccinees. Taken to-
gether, these results suggest a possible correlation
between the capacity of rHBsAg to bind to monocytes
and the potential to interfere with the normal function
of monocytes.
The most likely explanation for the differences in
binding observed among the three rHBsAgpreparations
was a difference in the phosphatidylinositol content of
the particles. However, phospholipid content, and espe-
cially the amount of the charged phosphatidylinositol,
was nearly identical. Although phospholipid content
determines whether HBsAg particles can bind to
monocytes, the possibility that a defined region of the
S protein is involved in the interaction cannot be
excluded [Vanlandschoot et al., 2002b]. Therefore,
minor differences in folding among the three rHBsAg
preparations might perhaps affect binding. Such rear-
rangements may be the consequence of the different
properties of the yeast cells used for rHBsAgproduction,
different purification methods, or storage conditions.
However, all preparations were producedwith the same
stable transformed yeast strain, ruling out different
host properties. DVP93/1 was stored for some time at
208C before putting it at708C. HEF002 andHEP715
were stored at708C. It is doubtful that this incubation
at 208C is responsible for the high binding capacity of
DVP93/1, because other recent rHBsAg preparations,
all stored at 708C, showed either high or low binding
(data not shown). The possibility that different purifica-
tion conditions are an underlying determinant is
currently under investigation.
Although what causes the differences in binding to
CD14 positive cells is unclear, a correlation between
binding capacity and immunosuppression is suggested.
Whether the suppressive interaction of yeast-expressed
HBsAg with monocytes affects the anti-HBs levels after
immunization with pure rHBsAg, and whether this
immunosuppressive effect is retained after adsorption
of rHBsAg onto aluminum hydroxide, remains to be
determined.
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